Dogwood Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dogwood Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Dogwood Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.3M, a 80.6% decline year-over-year.
  • Dogwood Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$5.82M, a 8.99% increase year-over-year.
  • Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$5.45M, a 55.8% increase from 2022.
  • Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$12.3M, a 21.3% increase from 2021.
  • Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$15.6M, a 56.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$5.45M +$6.87M +55.8% Jan 1, 2023 Dec 31, 2023 10-K/A 2024-03-08
2022 -$12.3M +$3.33M +21.3% Jan 1, 2022 Dec 31, 2022 10-K/A 2024-03-08
2021 -$15.6M -$5.64M -56.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$10M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.